Baxter Class Action Lawsuit: 8 Frequently Asked Questions

Introduction to the Baxter Class Action Lawsuit

• Baxter Class Action Lawsuit:  The Baxter class action lawsuit seeks to represent purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022, and July 30, 2025, inclusive (the “Class Period”).  Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., No. 25-cv-12672 (N.D. Ill.), the Baxter class action lawsuit charges Baxter and certain of Baxter’s top current and former executives with violations of the Securities Exchange Act of 1934.

• Contact Timothy L. Miles: If you suffered substantial losses and wish to serve as lead plaintiff of the Baxter class action lawsuit or just have general questions about your rights as a shareholder, please contact, at no charge, attorney Timothy L. Miles or at 855-846-6529 or via e-mail at [email protected].

5. How Do I Get Involved in the Baxter class action lawsuit?

• If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.

• You may be notified of a class action by mail if you are an eligible class member.

• You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.

• If you believe you may have a claim, you can contact a securities class action law firm for guidance. 

6. What Are the Allegations in the Baxter class action lawsuit?

Company

Baxter, through its subsidiaries, provides a portfolio of healthcare products.

False and Misleading Statements

The Baxter class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:

• (i) Baxter’s Novum IQ Large Volume Pump (“Novum LVP”) suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death;(ii) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects;

• (iii) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; and

• (iv) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps.

Corrective Disclosure

The Baxter class action lawsuit further alleges that on July 31, 2025, Baxter announced that it had decided to “voluntarily and temporarily pause shipments and planned installations of the Novum LVP” and that it was “unable to currently commit to an exact timing for resuming shipment and installation for Novum IQ LVPs.”

• Defendants further stated that they had offered “customers the option of our Spectrum infusion pump as an alternative” and that Baxter’s low-end guidance assumes that Baxter does not resume shipments for Novum LVPs before the end of the year, according to the complaint.

• The Baxter class action lawsuit alleges that on this news, the price of Baxter common stock fell more than 22%.

7. When is the Lead Plaintiff Deadline in the Baxter Class Action Lawsuit?

To be eligible for appointment as the lead plaintiff in the Baxter class action lawsuit, an investor must meet the following criteria:

• Securities Acquisition: The investor must have been purchasers or acquirers of Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

• Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Baxter and its executives.

• Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.